Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Non-prescription Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.9% during the forecast period.
This report presents the market size and development trends by detailing the Non-prescription Drugs market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Non-prescription Drugs market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Non-prescription Drugs industry and will help you to build a panoramic view of the industrial development.
Non-prescription Drugs Market, By Type:
Brand Drugs
Generic Drug
Non-prescription Drugs Market, By Application:
Hospital
Clinic
Other
Some of the leading players are as follows:
Boehringer Ingelheim
Bayer
Merck & Co (MSD)
Allergan
Teva
AstraZeneca
Gilead Sciences
Amgen
Eli Lilly
Shire
Novartis
Bristol-Myers Squibb
Roche
Sanofi
Johnson & Johnson
AbbVie
Merck & Co. (MSD)
GlaxoSmithKline (GSK)
Novo Nordisk
Takeda
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Non-prescription Drugs Market: Technology Type Analysis
-
4.1 Non-prescription Drugs Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Non-prescription Drugs Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Brand Drugs
4.3.2 Generic Drug
5 Non-prescription Drugs Market: Product Analysis
-
5.1 Non-prescription Drugs Product Market Share Analysis, 2018 & 2026
-
5.2 Non-prescription Drugs Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Non-prescription Drugs Market: Application Analysis
-
6.1 Non-prescription Drugs Application Market Share Analysis, 2018 & 2026
-
6.2 Non-prescription Drugs Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Hospital
6.3.2 Clinic
6.3.3 Other
7 Non-prescription Drugs Market: Regional Analysis
-
7.1 Non-prescription Drugs Regional Market Share Analysis, 2018 & 2026
-
7.2 Non-prescription Drugs Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 Boehringer Ingelheim
9.1.1 Boehringer Ingelheim Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Bayer
9.2.1 Bayer Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 Merck & Co (MSD)
9.3.1 Merck & Co (MSD) Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Allergan
9.4.1 Allergan Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Teva
9.5.1 Teva Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 AstraZeneca
9.6.1 AstraZeneca Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 Gilead Sciences
9.7.1 Gilead Sciences Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 Amgen
9.8.1 Amgen Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 Eli Lilly
9.9.1 Eli Lilly Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 Shire
9.10.1 Shire Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 Novartis
9.11.1 Novartis Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
9.12 Bristol-Myers Squibb
9.12.1 Bristol-Myers Squibb Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.12.5 SWOT analysis
9.13 Roche
9.13.1 Roche Company overview
9.13.2 Financial performance
9.13.3 Product benchmarking
9.13.4 Strategic initiatives
9.13.5 SWOT analysis
9.14 Sanofi
9.14.1 Sanofi Company overview
9.14.2 Financial performance
9.14.3 Product benchmarking
9.14.4 Strategic initiatives
9.14.5 SWOT analysis
9.15 Johnson & Johnson
9.15.1 Johnson & Johnson Company overview
9.15.2 Financial performance
9.15.3 Product benchmarking
9.15.4 Strategic initiatives
9.15.5 SWOT analysis
9.16 AbbVie
9.16.1 AbbVie Company overview
9.16.2 Financial performance
9.16.3 Product benchmarking
9.16.4 Strategic initiatives
9.16.5 SWOT analysis
9.17 Merck & Co. (MSD)
9.17.1 Merck & Co. (MSD) Company overview
9.17.2 Financial performance
9.17.3 Product benchmarking
9.17.4 Strategic initiatives
9.17.5 SWOT analysis
9.18 GlaxoSmithKline (GSK)
9.18.1 GlaxoSmithKline (GSK) Company overview
9.18.2 Financial performance
9.18.3 Product benchmarking
9.18.4 Strategic initiatives
9.18.5 SWOT analysis
9.19 Novo Nordisk
9.19.1 Novo Nordisk Company overview
9.19.2 Financial performance
9.19.3 Product benchmarking
9.19.4 Strategic initiatives
9.19.5 SWOT analysis
9.20 Takeda
9.20.1 Takeda Company overview
9.20.2 Financial performance
9.20.3 Product benchmarking
9.20.4 Strategic initiatives
9.20.5 SWOT analysis
The List of Tables and Figures (Totals 81 Figures and 140 Tables)
Figure Brand Drugs Non-prescription Drugs market, 2015 - 2026 (USD Million)
Figure Generic Drug Non-prescription Drugs market, 2015 - 2026 (USD Million)
Figure Hospital market, 2015 - 2026 (USD Million)
Figure Clinic market, 2015 - 2026 (USD Million)
Figure Other market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Non-prescription Drugs market, by country, 2015 - 2026 (USD Million)
-
Table North America Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table North America Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table North America Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Canada Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Canada Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Europe Non-prescription Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Europe Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Europe Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Europe Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Germany Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Germany Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table France Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table France Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Italy Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Italy Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Spain Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Spain Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Non-prescription Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table China Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table China Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Japan Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Japan Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table India Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table India Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Non-prescription Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table MEA Non-prescription Drugs market, by country, 2015 - 2026 (USD Million)
-
Table MEA Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table MEA Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table MEA Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Non-prescription Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Non-prescription Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Non-prescription Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table Boehringer Ingelheim Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bayer Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Merck & Co (MSD) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Allergan Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Teva Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Gilead Sciences Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Amgen Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Eli Lilly Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Shire Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Novartis Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bristol-Myers Squibb Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Roche Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Sanofi Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Johnson & Johnson Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table AbbVie Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Merck & Co. (MSD) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table GlaxoSmithKline (GSK) Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Novo Nordisk Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Takeda Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
